Navigation Links
Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
Date:8/13/2008

-- Conference Call on Wednesday, August 13, 2008 at 9:00 a.m. ET --

BEIJING, Aug. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's financial results for the six and three-month periods ended June 30, 2008.

Second Quarter Highlights

-- Sales increased 73% year-over-year to $16.5 million

-- Sold 2.72 million doses of Healive(R), up 55%, and 180,000 doses of

Bilive(R) based on increased demand following the May 12th earthquake

in Sichuan Province.

-- Gross profit grew 69% year-over-year to $13.9 million, with 84% gross

margin

-- Operating income rose 50% year-over-year to $7.0 million

-- Net income increased to $3.3 million with diluted EPS of $0.08

Year to Date Highlights

-- Sales increased 88% to $25.4 million

-- Operating income rose 66% year-over-year to $10.2 million

-- Net income increased to $4.9 million with diluted EPS of $0.12

Mr. Weidong Yin, Chairman, President and CEO, commented, "We are pleased to announce our record performance for this quarter, which can be attributed to Healive sales that exceeded market expectation. The devastating May 2008 earthquake in the Sichuan province resulted in health challenges presented by the destruction of clean water and sanitation infrastructure. In the face of this tragedy, we are proud to have been able to meet the increased demand for the hepatitis A vaccine after Sinovac was selected by Ministry of Health and provincial governments as the sole supplier of hepatitis A vaccine to the region. This illustrates the government's trust in the quality of our vaccines and our capability to provide comprehensive marketing and sales service and support to the local CDC and demonstrates that we have the production capacity and reliable delivery channel to fulfill urgent demand on a timely basis. We believe the experienc
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
2. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
3. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
4. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
5. Sinovac Biotech Holds Annual General Meeting
6. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
7. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
8. Sinovac Announces Adjournment of Annual General Meeting
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Sinovac Closes $9.75 Million Private Placement
11. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
(Date:8/20/2014)... Group finds that the vascular access device market in ... and China (BRIC) was valued ... of the United States market that year. ... as a result of strong economic expansion, improving access to healthcare ... Resources Group,s coverage of the BRIC vascular access device market: ...
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
Breaking Biology Technology:SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... Bulletin Board: TBIO ) today announced that ... Director for Laboratory Services.  In this newly created position ... vision and managing the day-to-day operations of Transgenomic,s Molecular ... to Transgenomic nearly 20 years of genetics experience in ...
... 21 Sermo ( http://www.sermo.com ), the largest online ... titled, " Physician Participation in the ESA REMS Program ... in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation and ... results, 83% of Hematologists/Oncologists view the ESA REMS program ...
... HIGHLIGHTS:   2010 Results (all percentages are ... reported sales increased 5% to $563 million. Excluding foreign currency exchange ... for SAFC (Fine Chemicals) and Research Products increased 12% and 3%, ... and 5%, respectively. Q3 2010 reported diluted EPS ...
Cached Biology Technology:Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 2Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 3Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 4Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 12
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... State University have developed a novel and versatile modeling ... for creating new materials as well as for studying ... allows us to model much larger and more complex ... says Nan Li, lead author of a paper on ... Department of Materials Science and Engineering. "This is a ...
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Engineering Conferences International (ECI) ( info@engconfintl.org ... XII Conference ( http://www.engconfintl.org/10ac.html ) are proud ... the winner of the 2010 Cell Culture ... Professor of Chemical and Biomolecular Engineering, at ...
... the Iberian Peninsula usually exceed the protection threshold established by ... according to data gathered between 2000 and 2005 by four ... Doana National Park. The limits established to protect human ... usually exceeded from April onwards, especially during the summer, in ...
... Langone Medical Center researchers have developed a powerful new method ... genes and examine how the process goes wrong in cancer ... research and described in the April 9 issue of ... DNA, a process required for gene activation. "The ...
Cached Biology News:Michael Betenbaugh wins 2010 Cell Culture Engineering award 2Ozone levels tend to be above recommended levels at this time of year in South West Spain 2Powerful new method allows scientists to probe gene activation 2
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: